SLAMF7 and neoplasm: As shown in Fig. 6, MM.1S-eGFP xenograft mice that received CS1-dbBiTE-armed T cells were able to control tumor burden 4–5 weeks post treatment depicted by a reduction in flux compared to untreated mice and MM.1S-CS1KO engrafted mice treated with CS1-dbBiTE (Fig. 6B).